Added-value porous materials for controlled thymol release obtained by supercritical CO 2 impregnation process
Source abstract
Abstract
This study explores utilization of biodegradable and biocompatible polymers for controlled release of natural bioactive substance. For that purpose, poly(ε-caprolactone) (PCL) beads, cellulose acetate (CA) film, and poly lactic- co-glycolic acid (PLGA) flakes were impregnated with thymol by employing environmentally friendly process of supercritical carbon dioxide (scCO 2 ) impregnation. At selected pressure and temperature, prolongation of operating time increased thymol loading. Pure scCO 2 did not affect CA film with average pore diameter of approximately 3 µm, while it enabled change of PCL beads and PLGA flakes into foams with average pore diameter approximately 175 µm and 87 µm, respectively. Additionally to scCO 2 , thymol acted as a plasticizer increasing pore size of polymers up to three times. Kinetic of thymol release from selected samples was tested using phosphate buffer saline at 37°C and successfully described with Korsmeyer–Peppas, zero-order, first-order, and Higuchi models. The suggested method of PCL, CA, and PLGA supercritical impregnation led to development of porous, solvent free, added-value materials that release thymol in a controlled manner from 5 h to several days.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: biodegradable polymer synthesis and properties · Polymer Foaming and Composites · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Technology and Metallurgy, University of Belgrade, Department of Organic Chemical Technology, Karnegijeva 4, Belgrade, Serbia
Innovation Center of the Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, Belgrade, Serbia
Funding
Ministry of Education, Science and Technological Development of Republic of Serbia
References (29)
Show source-provided references
1. 10.1517/1742524100360225910.1517/17425241003602259 ↗
2. Dash S · Acta Pol Pharm · 2010 · 67 · 217
3. Zamani Z · Iran J Pharm Res · 2015 · 14 · 1031
4. 10.1016/j.supflu.2015.07.00110.1016/j.supflu.2015.07.001 ↗
5. 10.1002/polb.2225910.1002/polb.22259 ↗
6. 10.1016/j.carbpol.2018.06.07210.1016/j.carbpol.2018.06.072 ↗
7. 10.1002/app.3868310.1002/app.38683 ↗
8. 10.1016/j.ijfoodmicro.2011.02.01110.1016/j.ijfoodmicro.2011.02.011 ↗
9. Meeran MFN · Front Pharmacol · 2017 · 8 · 1
10. 10.1016/j.ijpharm.2011.01.06310.1016/j.ijpharm.2011.01.063 ↗
11. 10.1016/j.eurpolymj.2017.01.01910.1016/j.eurpolymj.2017.01.019 ↗
12. 10.1016/j.supflu.2013.10.00310.1016/j.supflu.2013.10.003 ↗
13. 10.1016/j.jcou.2018.04.01910.1016/j.jcou.2018.04.019 ↗
14. 10.1016/j.supflu.2015.03.02210.1016/j.supflu.2015.03.022 ↗
15. 10.1016/j.supflu.2018.05.02510.1016/j.supflu.2018.05.025 ↗
16. 10.1002/star.20140013410.1002/star.201400134 ↗
17. 10.1016/j.jconrel.2015.05.00210.1016/j.jconrel.2015.05.002 ↗
18. 10.1016/j.supflu.2011.12.00210.1016/j.supflu.2011.12.002 ↗
19. 10.5937/tehnika1801017A10.5937/tehnika1801017A ↗
20. 10.1016/j.supflu.2018.02.01410.1016/j.supflu.2018.02.014 ↗
21. 10.22203/eCM.v014a0710.22203/eCM.v014a07 ↗
22. 10.1016/0168-3659(87)90034-410.1016/0168-3659(87)90034-4 ↗
23. 10.1088/1742-6596/215/1/01208710.1088/1742-6596/215/1/012087 ↗
24. 10.1016/j.supflu.2017.11.01310.1016/j.supflu.2017.11.013 ↗
25. 10.1177/02624893150340060310.1177/026248931503400603 ↗
26. 10.1089/ten.teb.2012.043710.1089/ten.teb.2012.0437 ↗
27. 10.1016/j.supflu.2018.10.00810.1016/j.supflu.2018.10.008 ↗
28. 10.1016/j.supflu.2011.05.00910.1016/j.supflu.2011.05.009 ↗
29. 10.1016/j.carbpol.2016.03.09310.1016/j.carbpol.2016.03.093 ↗